INGELHEIM, Germany & DUBAI & JORDAN--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only. Over 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition (non-valvular atrial fibrillation, nvAF).1 The 100th approval was announced by the Jordan Food and Drug Administration. Further regulatory approvals for Pradaxa® are expected to be received in the near future.
Help employers find you! Check out all the jobs and post your resume.
